WO2003027295A3 - Procedes de diagnostic et de traitement de maladies associees a l'expression alteree de la jak1 - Google Patents

Procedes de diagnostic et de traitement de maladies associees a l'expression alteree de la jak1 Download PDF

Info

Publication number
WO2003027295A3
WO2003027295A3 PCT/IB2002/004197 IB0204197W WO03027295A3 WO 2003027295 A3 WO2003027295 A3 WO 2003027295A3 IB 0204197 W IB0204197 W IB 0204197W WO 03027295 A3 WO03027295 A3 WO 03027295A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosis
treatment
methods
jak1
diseases associated
Prior art date
Application number
PCT/IB2002/004197
Other languages
English (en)
Other versions
WO2003027295A2 (fr
Inventor
Finn Skou Pedersen
Annette Balle Sorensen
Javier Martin Hernandez
Original Assignee
Univ Aarhus
Finn Skou Pedersen
Annette Balle Sorensen
Javier Martin Hernandez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/962,929 external-priority patent/US20020115058A1/en
Priority claimed from US09/963,131 external-priority patent/US20030224460A1/en
Priority claimed from US09/962,855 external-priority patent/US20020164576A1/en
Priority claimed from US09/962,854 external-priority patent/US20030044803A1/en
Application filed by Univ Aarhus, Finn Skou Pedersen, Annette Balle Sorensen, Javier Martin Hernandez filed Critical Univ Aarhus
Publication of WO2003027295A2 publication Critical patent/WO2003027295A2/fr
Publication of WO2003027295A3 publication Critical patent/WO2003027295A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne de nouvelles compositions et de nouveaux procédés concernant la JAK1 et destinés au dagnostic et au traitement du lymphome et de la leucémie. La présente invention concerne également l'utilisation de ces nouvelles compositions destinées à être utilisées dans des procédés de dépistage.
PCT/IB2002/004197 2001-09-24 2002-09-24 Procedes de diagnostic et de traitement de maladies associees a l'expression alteree de la jak1 WO2003027295A2 (fr)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US09/962,929 US20020115058A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of Pik3r1
US09/962,929 2001-09-24
US09/963,131 US20030224460A1 (en) 2000-09-22 2001-09-24 Novel compositions and methods for lymphoma and leukemia
US09/962,855 US20020164576A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of Nrf2
US09/962,916 2001-09-24
US09/962,916 US20030077590A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
US09/962,854 US20030044803A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of JAK1
US09/962,854 2001-09-24
US09/962,855 2001-09-24
US09/963,131 2001-09-24

Publications (2)

Publication Number Publication Date
WO2003027295A2 WO2003027295A2 (fr) 2003-04-03
WO2003027295A3 true WO2003027295A3 (fr) 2003-10-16

Family

ID=27542309

Family Applications (5)

Application Number Title Priority Date Filing Date
PCT/IB2002/004134 WO2003027276A2 (fr) 2001-09-24 2002-09-24 Nouvelles compositions et procedes relatifs aux lymphomes et aux leucemies
PCT/IB2002/004123 WO2003027320A2 (fr) 2001-09-24 2002-09-24 Methodes de diagnostic et de traitement de maladies associees a l'expression modifiee de pik3r1
PCT/IB2002/004158 WO2003027321A2 (fr) 2001-09-24 2002-09-24 Methodes de diagnostic et de traitement de maladies associees a une expression alteree de neurogranine
PCT/IB2002/004197 WO2003027295A2 (fr) 2001-09-24 2002-09-24 Procedes de diagnostic et de traitement de maladies associees a l'expression alteree de la jak1
PCT/IB2002/005830 WO2003043565A2 (fr) 2001-09-24 2002-09-24 Methodes de diagnostic et de traitement de maladies associees a l'expression modifiee de nrf2

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PCT/IB2002/004134 WO2003027276A2 (fr) 2001-09-24 2002-09-24 Nouvelles compositions et procedes relatifs aux lymphomes et aux leucemies
PCT/IB2002/004123 WO2003027320A2 (fr) 2001-09-24 2002-09-24 Methodes de diagnostic et de traitement de maladies associees a l'expression modifiee de pik3r1
PCT/IB2002/004158 WO2003027321A2 (fr) 2001-09-24 2002-09-24 Methodes de diagnostic et de traitement de maladies associees a une expression alteree de neurogranine

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/005830 WO2003043565A2 (fr) 2001-09-24 2002-09-24 Methodes de diagnostic et de traitement de maladies associees a l'expression modifiee de nrf2

Country Status (2)

Country Link
AU (4) AU2002337442A1 (fr)
WO (5) WO2003027276A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1959969A2 (fr) * 2005-07-01 2008-08-27 The Johns Hopkins University Compositions et procedes pour traiter ou prevenir des troubles associes au stress oxydatif
WO2007095321A2 (fr) * 2006-02-14 2007-08-23 President And Fellows Of Harvard College Genes de la progression mitotique et procedes permettant de reguler la mitose

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003358A1 (fr) * 1995-07-07 1997-01-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Procede pour identifier des inhibiteurs de la voie de transduction de signaux jak-stat
US5821069A (en) * 1993-06-30 1998-10-13 Ludwig Institute For Cancer Research Method for determining tyrosine kinase in a sample
WO1998053103A1 (fr) * 1997-05-21 1998-11-26 Clontech Laboratories, Inc. Ensembles d'acide nucleique
WO1999054286A2 (fr) * 1998-04-17 1999-10-28 Parker Hughes Institute Inhibiteurs btk et leurs procedes d'identification et d'utilisation
WO2001017995A1 (fr) * 1999-09-10 2001-03-15 Merck & Co., Inc. Inhibiteurs de tyrosine kinase
WO2002060492A1 (fr) * 2001-01-30 2002-08-08 Cytopia Pty Ltd Procedes d'inhibition de kinases
WO2002060927A1 (fr) * 2001-01-30 2002-08-08 Cytopia Pty Ltd Signalisation de la proteine kinase
WO2002070742A1 (fr) * 2001-03-01 2002-09-12 Epigenomics Ag Procede de mise au point de groupes d'echantillons de genes a des fins de diagnostic et de therapie qui sont bases sur l'expression et l'etat de methylation des genes
WO2003026641A2 (fr) * 2001-09-22 2003-04-03 University Of Nottingham Modulation de l'activite de stat

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ237669A (en) * 1990-04-13 1992-08-26 Res Dev Foundation T-cell proteins expressed in t-cell development and their preparation
US6300058B1 (en) * 1992-01-29 2001-10-09 Hitachi Chemical Research Center, Inc. Method for measuring messenger RNA
WO1998016557A1 (fr) * 1996-10-11 1998-04-23 The General Hospital Corporation Dosages pour recepteurs lies a la proteine g
US6133419A (en) * 1996-11-01 2000-10-17 Onyx Pharmaceuticals, Inc. Nucleotide sequences that encode phosphatidylinositol-3' kinase associated proteins and uses thereof
US5994076A (en) * 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
EP1053319A2 (fr) * 1998-01-28 2000-11-22 Chiron Corporation Genes humains et expression de produits genetiques ii
CA2321132A1 (fr) * 1998-02-23 1999-08-26 Andrei V. Gudkov Secretion de facteurs inhibiteurs de croissance dependant de p53
DE19817947A1 (de) * 1998-04-17 1999-10-28 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Myometrium-Tumorgewebe
WO1999065928A2 (fr) * 1998-06-19 1999-12-23 Genzyme Corporation Population de polynucleotides isoles de tissus mammaires tumoraux metastatiques ou non metastatiques
US6100090A (en) * 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
CA2358086A1 (fr) * 1998-12-22 2000-06-29 Myriad Genetics, Inc. Interactions proteine-proteine dans les troubles neurodegeneratifs
US6110664A (en) * 1999-06-25 2000-08-29 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-S1 expression
GB9917165D0 (en) * 1999-07-22 1999-09-22 Knoll Ag Polypeptides polynuclcotides and uses thereof
AU2470101A (en) * 1999-10-25 2001-05-08 Affymetrix, Inc. Genetic sequences associated with neural cell proliferation and disease
WO2001034633A2 (fr) * 1999-11-12 2001-05-17 Fred Hutchinson Cancer Research Center Methodes de traitement de la forme humaine de la maladie de huntington et methodes de criblage d'agents actifs
EP1250456A2 (fr) * 2000-01-07 2002-10-23 Curagen Corporation Acides nucleiques renfermant des polymorphismes de nucleotide simple et procede d'utilisation associe
WO2001057189A2 (fr) * 2000-02-07 2001-08-09 Quark Biotech, Inc. Genes de la voie fas
PT1939203E (pt) * 2000-04-25 2015-02-04 Icos Corp Inibidores da isoforma delta da fosfatidil-inositol 3-quinase humana
CN1173975C (zh) * 2000-04-27 2004-11-03 山之内制药株式会社 咪唑并吡啶衍生物
CA2411278A1 (fr) * 2000-06-09 2001-12-20 Corixa Corporation Compositions et procedes pour la therapie et le diagnostic du cancer du colon
JP2004527218A (ja) * 2000-09-08 2004-09-09 ニューヨーク・ユニバーシティ 紫外線応答性皮膚損傷の検出に有用な遺伝子マーカー
US6794137B2 (en) * 2000-09-08 2004-09-21 New York University Gene markers useful for detecting skin damage in response to ultraviolet radiation
EP1362122A2 (fr) * 2000-09-12 2003-11-19 TransGenetics Incorporated Organisation en micro-reseaux de genes cibles de facteur de transcription
AU2001290965A1 (en) * 2000-09-13 2002-03-26 Archemix Corporation Target activated nucleic acid biosensor and methods of using same
WO2002040637A2 (fr) * 2000-11-20 2002-05-23 Isis Pharmaceuticals, Inc. Modulation antisens de l'expression de pi3k p85
WO2002059367A2 (fr) * 2000-11-30 2002-08-01 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Jeu de microechantillons de diagnostic pour ibd, maladie de crohn et colite ulcereuse
AU2002330039A1 (en) * 2001-09-17 2003-04-01 Eos Biotechnology, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821069A (en) * 1993-06-30 1998-10-13 Ludwig Institute For Cancer Research Method for determining tyrosine kinase in a sample
WO1997003358A1 (fr) * 1995-07-07 1997-01-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Procede pour identifier des inhibiteurs de la voie de transduction de signaux jak-stat
WO1998053103A1 (fr) * 1997-05-21 1998-11-26 Clontech Laboratories, Inc. Ensembles d'acide nucleique
WO1999054286A2 (fr) * 1998-04-17 1999-10-28 Parker Hughes Institute Inhibiteurs btk et leurs procedes d'identification et d'utilisation
WO2001017995A1 (fr) * 1999-09-10 2001-03-15 Merck & Co., Inc. Inhibiteurs de tyrosine kinase
WO2002060492A1 (fr) * 2001-01-30 2002-08-08 Cytopia Pty Ltd Procedes d'inhibition de kinases
WO2002060927A1 (fr) * 2001-01-30 2002-08-08 Cytopia Pty Ltd Signalisation de la proteine kinase
WO2002070742A1 (fr) * 2001-03-01 2002-09-12 Epigenomics Ag Procede de mise au point de groupes d'echantillons de genes a des fins de diagnostic et de therapie qui sont bases sur l'expression et l'etat de methylation des genes
WO2003026641A2 (fr) * 2001-09-22 2003-04-03 University Of Nottingham Modulation de l'activite de stat

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ARINGER M ET AL: "Janus kinases and their role in growth and disease.", LIFE SCIENCES, vol. 64, no. 24, 7 May 1999 (1999-05-07), pages 2173 - 2186, XP002250017, ISSN: 0024-3205 *
ENDO T A ET AL: "A new protein containing an SH2 domain that inhibits JAK kinases", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 387, 26 June 1997 (1997-06-26), pages 921 - 924, XP002085492, ISSN: 0028-0836 *
HOFMANN WOLF-K ET AL: "Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 98, no. 3, 1 August 2001 (2001-08-01), pages 787 - 794, XP002246867, ISSN: 0006-4971 *
TSOU ANN-PING ET AL: "Parallel hybridization analysis of multiple protein kinase genes: Identification of gene expression patterns characteristic of human hepatocellular carcinoma.", GENOMICS, vol. 50, no. 3, 15 June 1998 (1998-06-15), pages 331 - 340, XP002250070, ISSN: 0888-7543 *
WILKS A F ET AL: "TWO NOVEL PROTEIN-TYROSINE KINASES, EACH WITH A SECOND PHOSPHOTRANSFERASE-RELATED CATALYTIC DOMAIN, DEFINE A NEW CLASS OF PROTEIN KINASE", MOLECULAR AND CELLULAR BIOLOGY, WASHINGTON, DC, US, vol. 11, no. 4, 1 April 1991 (1991-04-01), pages 2057 - 2065, XP000672768, ISSN: 0270-7306 *
YANG XIANJIE ET AL: "Molecular cloning of the murine JAK1 protein tyrosine kinase and its expression in the mouse central nervous system.", JOURNAL OF NEUROSCIENCE, vol. 13, no. 7, 1993, pages 3006 - 3017, XP008019210, ISSN: 0270-6474 *
YU C L ET AL: "Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 1 DEC 1997, vol. 159, no. 11, 1 December 1997 (1997-12-01), pages 5206 - 5210, XP002250016, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
AU2002329000A1 (en) 2003-04-07
AU2002364889A8 (en) 2003-06-10
WO2003027295A2 (fr) 2003-04-03
WO2003027276A3 (fr) 2004-02-12
AU2002330713A1 (en) 2003-04-07
WO2003027321A3 (fr) 2003-11-06
AU2002364889A1 (en) 2003-06-10
WO2003027320A3 (fr) 2003-10-23
WO2003027321A2 (fr) 2003-04-03
WO2003043565A2 (fr) 2003-05-30
WO2003027320A2 (fr) 2003-04-03
AU2002337442A1 (en) 2003-04-07
WO2003043565A3 (fr) 2003-11-13
WO2003027276A2 (fr) 2003-04-03

Similar Documents

Publication Publication Date Title
WO2003008583A3 (fr) Nouvelles compositions et methodes relatives au cancer
EP2014669A3 (fr) Procédés et compositions de lutte contre le cancer
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
RS20060320A (en) Substituted indazole-o-glucosides
SG130189A1 (en) Substituted indole-o-glucosides
HK1096392A1 (en) Substituted heterocycles
IL216579A0 (en) Aminocyclohexyl ether derivatives and pharmaceutical compositions containing the same
UA86042C2 (en) Substituted indazole-o-glucosides
GB0111186D0 (en) Novel compounds
WO2003066661A3 (fr) Anticorps humains du dr4 et utilisations
TW200505875A (en) Novel compounds
WO2003045230A3 (fr) Compositions et procedes contre le cancer
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
WO2003057146A3 (fr) Compositions et procedes concernant le cancer
WO2002081745A3 (fr) Genes impliques dans l'osteogenese et procedes d'utilisation associes
WO2003053224A3 (fr) Nouvelles compositions et methodes contre le cancer
WO2003045324A3 (fr) 14-methyl-epothilones
WO2002024867A3 (fr) Nouvelles compositions et nouvelles methodes pour le diagnostic et le traitement des lymphomes et des leucemies
WO2004047757A3 (fr) Diagnostic et traitement des cancers hematopoietiques
WO2003035837A3 (fr) Nouvelles compositions et procedes relatifs au cancer
WO2004045545A3 (fr) Compositions et procedes destines au traitement du cancer, au criblage des composants anticancereux presumes et a l'estimation de l'evolution du cancer
WO2003039484A3 (fr) Nouvelles compositions et methodes pour le traitement du cancer
WO2003071933A3 (fr) Nouvelles compositions et procedes de traitement du cancer
WO2003027295A3 (fr) Procedes de diagnostic et de traitement de maladies associees a l'expression alteree de la jak1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP